Clinical trials: Ischemic Stroke, Cryptogenic
Stroke
Finding Atrial Fibrillation in Patients With Unexplained Stroke Using Longterm Cardiac Monitoring
The SURPRISE study investigates atrial fibrillation(AFIB) in patients with a previous unexplained stroke. It uses long term monitoring of the heart of up to three years, searching for paroxysmal atrial fibrillation(PAF) otherwise…
- Trial name
- SURPRISE (NCT01498146)
- Where
- Denmark
- Volunteers
- 85 people
- Sponsor
- Bispebjerg Hospital
Stroke, Stroke, Ischemic
MLC1501 Study Assessing Efficacy in Post STrOke Subjects With mOtor Deficits
This is a multi-center, randomized, double-blind, placebo-controlled trial of MLC1501 in patients with stroke. Eligible participants will be randomized in a 1:1:1 ratio to orally receive MLC1501 high-dose twice a day, MLC1501…
- Conditions
- Stroke, Stroke, Ischemic, Strokes Thrombotic, Stroke Sequelae
- Trial name
- MAESTOSO (NCT05289947)
- Testing
- MLC1501
- Where
- 11 sites in Philippines, Singapore
- Volunteers
- 303 people
- Sponsor
- Moleac Pte Ltd.
Patent Foramen Ovale, Cryptogenic Stroke
Encore PFO Closure Device - The PerFOrm Trial
The objective of this study is to establish reasonable assurance of safety, effectiveness, and noninferiority of the Encore PFO closure device when compared to any investigator chosen FDA-approved PFO closure device.
- Trial name
- NCT05537753
- Testing
- Encore PFO closure device, FDA-approved PFO closure device
- Where
- 8 sites in United States
- Volunteers
- 500 people
- Sponsor
- Encore Medical Inc.
Stroke, Foramen Ovale, Patent
Prospective Clinical Follow-up After the Percutaneous Closure of a Patent Foramen Ovale
Following a cryptogenic stroke, many patients are nowadays treated with the percutaneous closure of a patent foramen ovale (PFO), assuming that the aetiology of the stroke is secondary to a paradoxical embolism.
- Trial name
- PFO-HUG (NCT01149447)
- Where
- Switzerland
- Volunteers
- 200 people
- Sponsor
- University Hospital, Geneva
Stroke, PFO - Patent Foramen Ovale
Japan Post Marketing Surveillance of the GORE® CARDIOFORM Septal Occluder
The purpose of this post-marketing surveillance is to evaluate the effectiveness and safety of GORE® CARDIOFORM Septal Occluder under the post-marketing setting in Japan.
- Conditions
- Stroke, PFO - Patent Foramen Ovale, Cryptogenic Stroke, TIA
- Trial name
- GSO-PFO PMS (NCT05529901)
- Testing
- GORE® CARDIOFORM Septal Occluder
- Where
- Japan
- Volunteers
- 300 people
- Sponsor
- W.L.Gore & Associates
Cryptogenic Stroke, Atrial Fibrillation
Atrial Tachycardia as a Predictor of Atrial Fibrillation, Stroke and Mortality in Cryptogenic Stroke
There is few information about the association between supraventricular arrhythmia different from atrial fibrillation (AF) or atrial Flutter and the risk of stroke.
- Conditions
- Cryptogenic Stroke, Atrial Fibrillation, Atrial Tachycardia
- Trial name
- NCT02374359
- Testing
- follow-up
- Where
- Spain
- Volunteers
- 210 people
- Sponsor
- Corporacion Parc Tauli
Stroke, Transient Ischemic Attack
GORE® Septal Occluder Device for Patent Foramen Ovale (PFO) Closure in Stroke Patients
The primary objective is to determine if patent foramen ovale (PFO) closure with the GORE® HELEX® Septal Occluder or GORE® CARDIOFORM Septal Occluder plus antiplatelet medical management is safe and effective and reduces the risk…
- Trial name
- REDUCE (NCT00738894)
- Testing
- Septal Occluder Device, Antiplatelet Medical Therapy
- Where
- 2 sites in United States, Denmark
- Volunteers
- 664 people
- Sponsor
- W.L.Gore & Associates
Acute Ischemic Stroke
Plaque Imaging in Routine Care to Detect Intraplaque Hemorrhage
The aim of this study is to investigate the association between intraplaque hemorrhage (IPH) detected by non-contrast magnetic resonance imaging (MRI) of the carotid artery in routine clinical practice and ipsilateral acute…
- Trial name
- PARADE (NCT06749106)
- Where
- Germany
- Volunteers
- 300 people
- Sponsor
- Ludwig-Maximilians - University of Munich
Cryptogenic Stroke, Foramen Ovale, Patent
Atrial Fibrillation Before and After Patent Foramen Ovale Closure Study
The aim of the ALFA ROMEO study is to better understand the association between cryptogenic stroke, PFO, PFO closure and AF.
- Conditions
- Cryptogenic Stroke, Foramen Ovale, Patent, Atrial Fibrillation
- Trial name
- ALFA-ROMEO (NCT04881578)
- Testing
- continuous cardiac monitoring before and after transcatheter PFO closure
- Where
- 6 sites in Switzerland
- Volunteers
- 200 people
- Sponsor
- Raban Jeger
PFO, PFO - Patent Foramen Ovale
Evaluating Percutaneous Repair Of The Atrial Septum With A Novel PFO Occluder: The PROTEA-PFO OUS Study
The goal of this clinical trial is to test a new heart device called P3 Occluder System in patients who have a small opening between the upper chambers of the heart (called a Patent Foramen Ovale or PFO) and have experienced a…
- Conditions
- PFO, PFO - Patent Foramen Ovale, Cryptogenic Stroke, Patent Foramen Ovale
- Trial name
- PROTEA-PFO OUS (NCT07698951)
- Testing
- Recross P3 Occluder (P3O) System
- Where
- Serbia
- Volunteers
- 15 people
- Sponsor
- Recross Cardio, Inc.
Brain Infarction
Cortical Cerebellar Infarctions Associated With Patent Foramen Ovale in Young Stroke Patients
The investigator retrospectively analyzed consecutive young (<60 years) cryptogenic stroke patients with Patient Foramen Ovale (PFO) recruited between January 2016 and May 2019 in our center, and compared these patients with sex…
- Trial name
- NCT04043559
- Testing
- MRI scanner, Contrast transoesophageal echocardiography
- Where
- France
- Volunteers
- 50 people
- Sponsor
- Centre Hospitalier Universitaire de Nīmes
Patent Foramen Ovale, Stroke, Cryptogenic
PFO tRanscatether Occlusion Long-term Outcomes National Group (PROLONG) Registry
Patent foramen ovale (PFO) has been associated with cryptogenic stroke and transient ischemic attack (TIA) in young adults. Evidence from randomized clinical trials (RCT) has shown that transcatheter PFO closure yields a 59%…
- Conditions
- Patent Foramen Ovale, Stroke, Cryptogenic, Transient Ischaemic Attack Due to Embolism, Atrial Fibrillation New Onset
- Trial name
- PROLONG (NCT06504121)
- Testing
- Septal Occluder Device
- Volunteers
- 1,360 people
- Sponsor
- IRCCS Ospedale San Raffaele
Cryptogenic Symptomatic Transient Ischemic Attack, Cryptogenic Ischemic Stroke
Study of Continuous Cardiac Monitoring to Assess Atrial Fibrillation After Cryptogenic Stroke
The 2006 American Heart Association / American Stroke Association Council on Stroke Guidelines for Prevention of Stroke in Patients With Ischemic Stroke or Transient Ischemic recommended that patients with cryptogenic stroke take…
- Trial name
- CRYSTAL-AF (NCT00924638)
- Testing
- Reveal® XT Insertable Cardiac Monitor
- Where
- 55 sites in United States, Austria and 12 more
- Volunteers
- 447 people
- Sponsor
- Medtronic Cardiac Rhythm and Heart Failure
Patent Foramen Ovale
Internal Microstructure of Patent Foramen Ovale Related to Stroke
This study aims to (1) investigate the internal microstructure of patent foramen ovale related to cryptogenic stroke, transient ischemic attack or migraine and determine the effectiveness of transcatheter closure in these…
- Trial name
- IMPORT (NCT04686253)
- Testing
- not appliable
- Where
- 2 sites in China
- Volunteers
- 1,200 people
- Sponsor
- China National Center for Cardiovascular Diseases
Cryptogenic Ischemic Stroke, Patent Foramen Ovale
PFO Closure, Oral Anticoagulants or Antiplatelet Therapy After PFO-associated Stroke in Patients Aged 60 to 80 Years
To assess whether PFO closure plus antiplatelet therapy is superior to antiplatelet therapy alone and whether oral anticoagulant therapy is superior to antiplatelet therapy to prevent stroke recurrence in patients aged 60 to 80…
- Trial name
- CLOSE-2 (NCT05387954)
- Testing
- Transcatheter PFO closure, Oral Anticoagulant, Direct-Acting, Antiplatelet therapy
- Where
- 42 sites in France
- Volunteers
- 792 people
- Sponsor
- Assistance Publique - Hôpitaux de Paris
Foramen Ovale, Patent
The Paradigm II Trial: PFX Closure System in Subjects With Cryptogenic Stroke, Transient Ischemic Attack, Migraine or Decompression Illness
The primary objective of this study is to demonstrate the safety and efficacy of the PFX Closure System when utilized for patent foramen ovale (PFO) in patients suffering from cryptogenic stroke (undetermined cause of stroke)…
- Trial name
- NCT00196040
- Testing
- PFX Closure System
- Where
- Germany
- Volunteers
- 60 people
- Sponsor
- Cierra
Embolic Stroke of Undetermined Source
AI-Based Prediction of Atrial Fibrillation in ESUS Patients With ICM
This study investigates patients with Embolic Stroke of Undetermined Source (ESUS) who have received an Implantable Cardiac Monitor (ICM).
- Trial name
- SMART-ESUS (NCT07347691)
- Where
- 5 sites in South Korea
- Volunteers
- 92 people
- Sponsor
- Inha University Hospital
Cryptogenic Stroke, Atrial Fibrillation
Incidence and Predictors of Recurrent Stroke in Cryptogenic Stroke Patients With Atrial Fibrillation
Brief Summary: This study aimed to investigate the risk and factors that predict recurrent stroke in patients who initially had a stroke with no clear cause (called cryptogenic stroke) and were later found to have atrial…
- Conditions
- Cryptogenic Stroke, Atrial Fibrillation, Recurrent Ischemic Stroke
- Trial name
- NCT07126184
- Testing
- Extended Cardiac Monitoring
- Where
- Pakistan
- Volunteers
- 109 people
- Sponsor
- Nangarhar University
Patent Foramen Ovale, Ischemic Stroke
Discontinuation of Antithrombotic Treatment Following Patent Foramen Ovale Closure in Young Patients With Cryptogenic Stroke
To determine the safety of antithrombotic treatment discontinuation 12 months following successful transcatheter PFO closure.
- Conditions
- Patent Foramen Ovale, Ischemic Stroke, Bleeding Ulcer
- Trial name
- HALTI (NCT04475510)
- Testing
- Antiplatelet treatment discontinuation
- Where
- Canada
- Volunteers
- 100 people, healthy volunteers welcome
- Sponsor
- Josep Rodes-Cabau
Atrial Fibrillation, Stroke
Transient Electrocardiogram Assessment in Stroke Evaluation
In stroke survivors, atrial fibrillation is typically detected with short-term electrocardiogram (ECG) monitoring in the stroke unit.
- Trial name
- TEASE (NCT03301662)
- Testing
- chest and thumb- ECG
- Volunteers
- 100 people
- Sponsor
- Region Gävleborg